Loading organizations...
§ Venture Capital · San Francisco, CA, USA
Early-stage venture capital firm for Seed and Series A investments in software companies, focused on SaaS, B2B, and developer platforms.
Key people at Chemistry VC.
Chemistry VC is a San Francisco, California-based early-stage venture capital firm that leads investments in emerging software companies at the Seed and Series A stages. The firm focuses primarily on the software sector, targeting startups operating across software-as-a-service, developer platforms, data infrastructure, business-to-business applications, and gaming. Chemistry VC operates with a $350 million inaugural fund, writing initial checks ranging from $3 million to $30 million, with an average Series A allocation of $10 million to $12 million. The partnership team brings a collective track record from their previous tenures at other major funds, which includes early investments in recognizable technology companies such as PagerDuty, Intercom, and SendGrid. The firm recently led a $26 million Series B funding round for the medical technology startup Assort Health. Chemistry VC was founded recently by Ethan Kurzweil, Mark Goldberg, and Kristina Shen.
Chemistry VC is an early-stage venture capital firm founded in 2024 that focuses on investing in software startups at the Seed and Series A stages. Their mission centers on providing founders with deep technical expertise and commercial insight, combined with highly engaged, hands-on support. Chemistry’s investment philosophy emphasizes a lean, founder-focused approach, committing fully to each portfolio company rather than scaling rapidly. They write checks typically ranging from $3 million to $30 million, averaging $10-12 million for Series A rounds. The firm aims to back startups that are building sustainable, long-term businesses in a challenging funding environment, especially where Series A rounds have become more difficult to secure. Chemistry’s impact on the startup ecosystem lies in their dedication to founder success through active partnership and operational support, distinguishing themselves from larger, less personalized funds[1][2][3][4].
Chemistry was founded in 2024 by three experienced venture capitalists: Ethan Kurzweil (formerly of Bessemer Venture Partners), Mark Goldberg (formerly of Index Ventures), and Kristina Shen (formerly of Andreessen Horowitz and Bessemer). Each partner brought a strong track record of investing in successful startups such as PagerDuty, Twitch, Plaid, and Sprig. The idea for Chemistry emerged from their shared conviction that early-stage venture capital should focus intensely on founder relationships and operational support rather than rapid fund scaling. They launched the firm with a debut fund of $350 million, aiming to provide the kind of attention and expertise founders expect from top-tier VCs but with a more personalized approach. This founding ethos is reflected in their commitment to being the portfolio services team themselves, with no intermediaries between investors and founders[1][3][4].
Chemistry VC is riding the trend of a more disciplined and founder-centric venture capital environment, particularly in the post-2021 funding landscape where Series A rounds have become more challenging and seed-to-Series A timelines have lengthened. Their timing is critical as startups now need to build sustainable growth rather than rely on quick exits or inflated valuations. Market forces such as rising growth thresholds for IPOs and a more cautious capital environment favor firms like Chemistry that emphasize long-term value creation and operational partnership. By focusing on software startups and providing deep support, Chemistry influences the ecosystem by helping founders navigate tougher funding conditions and scale responsibly[1][2].
Looking ahead, Chemistry VC is well-positioned to continue shaping early-stage software investing by doubling down on founder engagement and operational excellence. As market dynamics push startups toward longer runways and higher growth expectations, Chemistry’s model of deep partnership and selective investment will likely gain further relevance. Trends such as increased scrutiny on unit economics, sustainable growth, and developer-focused software platforms will shape their portfolio’s trajectory. Chemistry’s influence may evolve from a boutique early-stage fund to a recognized leader in founder-first venture capital, setting a standard for how early-stage investors can add value beyond capital[1][2][4].
Key people at Chemistry VC.
Chemistry VC has more than 26 tracked investments across 24 companies. The latest tracked deal is $250.0M Series D in Decagon in January 2026.
